Mitomycin Exhibits Durable Responses in Recurrent, Low-Grade NMIBC
Written by
Cancer Network
Published
0
comments
0
min
Adverse reactions in the phase 3 ENVISION trial were largely mild to moderate in severity, and serious reactions occurred in 12% of those with NMIBC.